Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

USA - NASDAQ:TNXP - US8902608392 - Common Stock

19.5 USD
-0.51 (-2.55%)
Last: 10/15/2025, 8:03:51 PM
19.55 USD
+0.05 (+0.26%)
After Hours: 10/15/2025, 8:03:51 PM
Fundamental Rating

3

TNXP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. TNXP has a great financial health rating, but its profitability evaluates not so good. TNXP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TNXP had negative earnings in the past year.
In the past year TNXP has reported a negative cash flow from operations.
TNXP had negative earnings in each of the past 5 years.
TNXP had a negative operating cash flow in each of the past 5 years.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

TNXP has a Return On Assets (-43.46%) which is in line with its industry peers.
TNXP has a better Return On Equity (-48.47%) than 66.98% of its industry peers.
Industry RankSector Rank
ROA -43.46%
ROE -48.47%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 29.27%, TNXP is in the better half of the industry, outperforming 73.51% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNXP has more shares outstanding than it did 1 year ago.
TNXP has more shares outstanding than it did 5 years ago.
TNXP has a better debt/assets ratio than last year.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.96, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
TNXP has a Altman-Z score (-0.96) which is comparable to the rest of the industry.
TNXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.96
ROIC/WACCN/A
WACC9.67%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TNXP has a Current Ratio of 7.53. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.53, TNXP is in the better half of the industry, outperforming 71.27% of the companies in the same industry.
A Quick Ratio of 7.22 indicates that TNXP has no problem at all paying its short term obligations.
TNXP's Quick ratio of 7.22 is fine compared to the rest of the industry. TNXP outperforms 70.71% of its industry peers.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.22
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.64% over the past year.
TNXP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.09%.
EPS 1Y (TTM)99.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
Revenue 1Y (TTM)-21.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.51%

3.2 Future

Based on estimates for the next years, TNXP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.99% on average per year.
TNXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.28% yearly.
EPS Next Y99.48%
EPS Next 2Y41.3%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year-10.16%
Revenue Next 2Y204.72%
Revenue Next 3Y118.28%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500M -1B -1.5B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30

4.3 Compensation for Growth

TNXP's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.3%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

TNXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (10/15/2025, 8:03:51 PM)

After market: 19.55 +0.05 (+0.26%)

19.5

-0.51 (-2.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners15.84%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change3.33%
Market Cap171.01M
Analysts82.5
Price Target69.02 (253.95%)
Short Float %15.21%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.95%
Min EPS beat(2)-17.71%
Max EPS beat(2)13.8%
EPS beat(4)3
Avg EPS beat(4)46.48%
Min EPS beat(4)-17.71%
Max EPS beat(4)97.53%
EPS beat(8)5
Avg EPS beat(8)-26.06%
EPS beat(12)8
Avg EPS beat(12)-11.59%
EPS beat(16)10
Avg EPS beat(16)-6.96%
Revenue beat(2)0
Avg Revenue beat(2)-13.06%
Min Revenue beat(2)-19.5%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-16.01%
Min Revenue beat(4)-27.68%
Max Revenue beat(4)-6.61%
Revenue beat(8)0
Avg Revenue beat(8)-21.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.73%
PT rev (3m)-83.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.91%
EPS NY rev (1m)0%
EPS NY rev (3m)1.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.4
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-39.47
EYN/A
EPS(NY)-8.78
Fwd EYN/A
FCF(TTM)-7.46
FCFYN/A
OCF(TTM)-7.39
OCFYN/A
SpS1.12
BVpS19.16
TBVpS19.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.46%
ROE -48.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.27%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.5%
Cap/Sales 5.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.22
Altman-Z -0.96
F-Score5
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
EPS Next Y99.48%
EPS Next 2Y41.3%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.51%
Revenue Next Year-10.16%
Revenue Next 2Y204.72%
Revenue Next 3Y118.28%
Revenue Next 5YN/A
EBIT growth 1Y13.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.5%
OCF growth 3YN/A
OCF growth 5YN/A